Inhibition of PD-1 and VEGF in microsatellite-stable endometrial cancer
Mené sur 54 patientes atteintes d'un cancer de l'endomètre de stade avancé, cet essai de phase II évalue l'efficacité, du point de vue de la proportion de patientes obtenant une réponse objective en semaine 24, et la toxicité d'un traitement combinant lenvatinib et pembrolizumab (durée médiane de suivi : 13,3 mois)
A 2018 study showed that the incidence of endometrial cancer increased over the past 25 years in several countries, especially those undergoing rapid socioeconomic transitions. Although early-stage endometrial cancer is treatable with surgery and adjuvant therapy, long-term outcomes for patients with advanced disease are poor, and the activity of chemotherapy or hormonal therapy in this setting is very low. The US Food and Drug Administration's approval of the tumour-site-agnostic PD-1 inhibitor pembrolizumab for patients with high microsatellite instability solid tumours has given patients with high microsatellite instability endometrial cancer an effective new treatment option. However, only 20–30% of endometrial cancers have microsatellite instability, and PD-1 inhibition is much less efficacious in patients with microsatellite-stable disease
The Lancet Oncology , commentaire, 2018